Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, 4-arm, randomized, parallel-group study to evaluate safety
and tolerability of Brivaracetam Intravenous (BRV iv) as adjunctive treatment for adults with
epilepsy according to an initiation or a conversion scheme, during repeated dosing (100
mg/administration twice daily for 4.5 days).